Skip to main content

Evaluating the Effects of a 14-Day Oral Chemotherapy Dispensing Protocol on Adherence, Toxicity, and Cost

Audiocasts - Original Research
Shardae Young, PharmD, BCPS
Clinical Pharmacy Specialist
Oncology
at VA Texas Valley Coastal Bend Health Care System
Harlingen,TX.
Shardae Young, PharmD, BCPS, Clinical Pharmacy Specialist, Oncology, VA Texas Valley Coastal Bend Health Care System, Harlingen,TX, discusses the clinical significance of her study, “Evaluating the Effects of a 14-Day Oral Chemotherapy Dispensing Protocol on Adherence, Toxicity, and Cost.”
Related Items
Arthralgia Rates and Treatment Among Patients Receiving Bevacizumab-awwb Versus Bevacizumab
JHOP - August 2026 Vol 16, No 4 published on April 3, 2026 in Original Research, Adverse Events, Biosimilars
Glucarpi-CAP: A Retrospective Case Series of 1000-Unit Glucarpidase Dosing for Methotrexate Rescue
JHOP - December 2026 Vol 16, No 6 published on March 31, 2026 in Original Research, Methotrexate, Case Reports
Expanding Bispecific T-Cell Engager Therapy for Multiple Myeloma to Community Settings: A Single-Institution Experience
JHOP - December 2026 Vol 16, No 6 published on March 26, 2026 in Original Research, Bispecific Antibodies, Multiple Myeloma
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
JHOP - December 2026 Vol 16, No 6 published on March 25, 2026 in Original Research, Immunotherapy, Chemotherapy, Breast Cancer
Characterizing Lenalidomide Dose Modifications Among Black and Non-Black Patients Receiving Induction Therapy for Newly Diagnosed Multiple Myeloma
JHOP - October 2026 Vol 16, No 5 published on March 23, 2026 in Original Research, Adverse Events, Disparities in Oncology Care, Dose Escalation/Reduction, Immunotherapy, Multiple Myeloma
Outcomes of Early Versus Delayed Initiation of Immunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer
JHOP - August 2026 Vol 16, No 4 published on March 11, 2026 in Original Research, Lung Cancer, Immunotherapy, Adverse Events
Impact of Hyperglycemia During Immune Checkpoint Inhibitor Treatment for Advanced Non–Small Cell Lung Cancer: A Retrospective, Single-Center Study
JHOP - June 2026 Vol 16, No 3 published on February 25, 2026 in Original Research, Checkpoint Inhibitors, Adverse Events, Lung Cancer
Management Patterns and Perceived Educational Needs Related to Cancer Therapy Cardiovascular Toxicities for Cardio-Oncology Providers
JHOP - June 2026 Vol 16, No 3 published on February 19, 2026 in Original Research, Adverse Events, Drug–Drug Interaction
Risk for Vincristine-Induced Adverse Events With Aprepitant in Pediatric Patients With Rhabdomyosarcoma
JHOP - April 2026 Vol 16, No 2 published on January 20, 2026 in Original Research, Adverse Events, Chemotherapy, Drug–Drug Interaction
Infusion-Related Reactions Associated With Nivolumab and Pembrolizumab: A Case Series Analysis
JHOP - June 2026 Vol 16, No 3 published on January 8, 2026 in Original Research, Checkpoint Inhibitors, Infusion Issues, PD-1 Inhibitors